Skip to content

THRIVE and Non-intubated Thoracic Surgery

Efficacy and Safety of Transnasal Humidified Rapid-insufflation Ventilator Exchange (THRIVE) and Non-intubated Thoracic Surgery (NITS)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03275428
Enrollment
40
Registered
2017-09-07
Start date
2017-09-11
Completion date
2018-09-10
Last updated
2017-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxygenation, Thoracic Surgery

Keywords

THRIVE, Non-intubated thoracic surgery

Brief summary

Video assisted thoracic surgery utilizes small instruments to perform complicated thoracic surgeries. This minimally invasive technique leaves small wounds thus facilitate recovery. Traditionally, thoracic surgery required general anesthesia with double lumen endobronchial tube to facilitate one-lung ventilation. However, as anesthesia techniques improve, video assisted thoracic surgery can be achieved with minimal sedation and without intubation. Thoracic surgeries involve excision of lung tissue thus impair post-operative lung function, putting patients at high risk of cardiopulmonary complications. Non-intubate thoracic surgeries can avoid this complication by avoiding general anesthesia and intubation. Transnasal humidified rapid-insufflation ventilator exchange offers 30-50 L/min oxygen via nasal cannula, thus provide safe and comfortable way of oxygen supplementation. It is useful in intravenous sedated patients since they are prone to hypoxia from respiratory suppression and upper airway obstruction. This study is a matched case-control study to compare the efficacy and safety of Transnasal humidified rapid-insufflation ventilator exchange in non-intubated thoracic surgery versus double lumen endobronchial tube intubated general anesthesia.

Detailed description

Lung cancer has been a leading cause of death for years. There are more than 10,000 new cases in Taiwan. Delayed discovery of the disease is a reason for high mortality rate. Most cases are discovered after second stage. Early discovery of the disease rely on low dose CT scans. Early stage lung cancer patients are candidates for minimally invasive surgeries. Traditionally thoracomies and video-assisted thoracic surgeries require general anesthesia with double lumen endobronchial tubes. The technique of double lumen intubation and one lung ventilation causes respiratory complications and damage to the trachea, larynx and vocal cords. With the development of single port thoracotomies, anesthesia can be minimized as well. Patients receive an epidural, intercostal or paravertebral nerve block to decrease pain. Minimal anesthetic agents may be given to decrease anxiety or to induce light sedation. Patients does not need to be intubated and can maintain respiratory function and can recover quickly. Not only can video-assisted thoracic surgery be used in lung tumor treatment, it can also be used to threat esophageal and mediastinal lesions, pneumothorax or as a diagnostic tool. Video-assisted thoracic surgery was shown to decrease acute phase inflammatory reactions, decrease immunosuppression and can be beneficial for tumor treatment. The intravenous sedation medications used in non-intubate thoracic surgery decrease pain and anxiety. However, many will develop respiratory depression and upper airway obstruction. Also, spontaneous pneumothorax during surgery causes one lung ventilation. Traditional oxygen supply cannot meet the demand of non-intubated thoracic surgery. Transnasal humidified rapid-insufflation ventilator exchange offers 30-70 L/min oxygen via nasal cannula. Its humidified oxygen can decrease discomfort from cold dry gas. It also provides positive pressure to the airway thus decrease airway obstruction. Our hypothesis is that non-intubated thoracic surgery with transnasal humidified rapid-insufflation ventilator exchange can maintain optimal surgical condition such as maintain arterial oxygen pressure, decrease acute phase reactions, tumor suppression and accelerate recovery after surgery.

Interventions

DEVICEtransnasal humidified rapid-insufflation ventilator exchange

high flow nasal cannula with humidified oxygen

Sponsors

Taipei Veterans General Hospital, Taiwan
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Lung nodules requiring surgical resection * Resectable by video-assisted thoracic surgery

Exclusion criteria

* ASA class IV or V * Room air oxygen saturation by pulse oximeter \< 90% * Emergent surgery * Use of inotropics or vasoconstrictors * History of nasal surgery or cranial surgery * Abnormal coagulation profile * History of spinal surgery or trauma

Design outcomes

Primary

MeasureTime frameDescription
Arterial oxygen pressureFrom induction of anesthesia to surgical procedure to end of recovery room observation, duration of six hours.Capability of maintaining arterial oxygen pressure \> 100 mmHg from arterial blood gas analysis before anesthetic induction, during surgery and in recovery room.
Arterial carbon dioxide pressureFrom induction of anesthesia to surgical procedure to end of recovery room observation, duration of six hours.Capability of maintaining arterial carbon dioxide pressure \< 50 mmHg from arterial blood gas analysis before anesthetic induction, during surgery and in recovery room.
Duration of stayFrom admission to ward to discharge from ward, duration of 5 days to two weeks.Duration of stay as in days of admission in the hospital

Secondary

MeasureTime frameDescription
Acute phase reactionFrom induction of anesthesia to surgical procedure to fifth post-operative day, duration of six days.Measure of C-reactive protein from blood sample analysis before anesthetic induction, after tumor resection during surgery, on post-operative day 1, 3 and 5.
Immune cell countFrom induction of anesthesia to surgical procedure to fifth post-operative day, duration of six days.Measure of Immune cell count from blood sample analysis before anesthetic induction, after tumor resection during surgery,
InterleukinsFrom induction of anesthesia to surgical procedure to fifth post-operative day, duration of six days.Measure of interleukins from blood sample analysis before anesthetic induction, after tumor resection during surgery, on post-operative day 1, 3 and 5.
TNFFrom induction of anesthesia to surgical procedure to fifth post-operative day, duration of six days.Measure of interleukins from blood sample analysis before anesthetic induction, after tumor resection during surgery,

Countries

Taiwan

Contacts

Primary ContactChien-Kun Ting, MD, PhD
ckting@vghtpe.gov.tw+886-938593137

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026